Treatment of primary Sjogren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results
>Abstract
>Full Text(Arthritis Rheum.)
New approaches to the treatment of Sjogren's syndrome: soon beyond symptomatic relief?
>Abstract
>Full Text(Dermatology.)
Cytokine concentrations in stimulated whole saliva among patients with primary Sjogren's syndrome, secondary Sjogren's syndrome, and patients with primary Sjogren's syndrome receiving varying doses of interferon for symptomatic treatment of the condition: a preliminary study
>Abstract
>Full Text(Clin Oral Investig.)
A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjogren's syndrome
>Abstract
>Full Text(Oral Surg Oral Med Oral Pathol Oral Radiol Endod.)
Use of muscarinic agonists in the treatment of Sjogren's syndrome
>Abstract
>Full Text(Clin Immunol.)
Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial
>Abstract
>Full Text(Arch Intern Med.)
Use of orally administered anhydrous crystalline maltose for relief of dry mouth
>Abstract
>Full Text(J Altern Complement Med.)
Effects on local blood flux of acupuncture stimulation used to treat xerostomia in patients suffering from Sjogren's syndrome
>Abstract(J Oral Rehabil.)
A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren's syndrome patients with xerostomia and keratoconjunctivitis sicca
>Abstract
>Full Text(Arthritis Rheum.)
Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjogren's syndrome.IV immunoglobulin
>Abstract
>Full Text(Neurology.)
Treatment of primary Sjogren's syndrome with D-penicillamine: a pilot study
>Abstract(Neth J Med.)
Treatment of myelopathy in Sjogren syndrome with a combination of prednisone and cyclophosphamide
>Abstract
>Full Text(Arch Neurol.)
Sjogren's syndrome: current therapies remain inadequate for a common disease
>Abstract
>Full Text(Expert Opin Investig Drugs.)
General pharmacological profile of the novel muscarinic receptor agonist SNI-2011,
a drug for xerostomia in Sjogren's syndrome. 4th communication:
Effects on gastrointestinal, urinary and reproductive systems and other effects
>Abstract(Arzneimittelforschung.)
Myelopathy in primary Sjogren's syndrome: diagnostic and therapeutic aspects
>Abstract
>Full Text(Acta Neurol Scand.)
Improvement of lacrimal function by topical application of CyA in murine models of Sjogren's syndrome
>Abstract
>Full Text(Invest Ophthalmol Vis Sci.)
